PHOTOTHERAPY VERSUS PREGABALIN IN TREATMENT OF REFRACTORY UREAMIC PRURITIS
- Registration Number
- NCT04660773
- Lead Sponsor
- Alexandria University
- Brief Summary
Patients will be randomly assigned into 2 groups:
1. Group A: (20 patients) will receive NB UVB phototherapy 3 sessions per week for 2 months.
2. Group B: (20 patients) will receive pregabalin oral therapy (50mg after each dialysis session) for 2 months.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Age: 20-60 years.
- End stage renal disease (the last stage(stage 5) of chronic disease which means kidneys are only functioning at 10 to 15 percent of their normal capacity and dialysis or kidney transplant is necessary to stay alive).
- Refractory uremic pruritis.
Exclusion Criteria
- Other causes of pruritis (Dermatological or systemic) e.g. atopic, cholestatic liver disease.
- Photosensitivity.
- Contraindication or allergy to pregabalin.
- Patients on antipruritic drugs e.g. antihistamines, steroids, emollients, opioid agonists.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description NB UVB phototherapy NB UVB phototherapy (20 patients) will receive NB UVB phototherapy 3 sessions per week for 2 months. pregabalin Pregabalin 20 patients) will receive pregabalin oral therapy (50mg after each dialysis session) for 2 months.
- Primary Outcome Measures
Name Time Method 5 D-itching scale two month assessment of degree, duration, direction, disability and distribution of itching
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Faculty of Medicine
🇪🇬Alexandria, Egypt